1
George W Muller, David Stirling: Substituted 1-oxo- and 1,3-dioxoisoindoline and method of reducing inflammatory cytokine levels. Celgene Corporation, Brian L Buckwalter, Mathews Collins Shepherd & McKay P A, April 30, 2002: US06380239 (94 worldwide citation)

1-Oxo- and 1,3-dioxoisoindolines substituted in the 4- or 5-position of the indoline ring reduce the levels of inflammatory cytokines such as TNF&agr; in a mammal. A typical embodiment is 4-(4-amino-1,3-dioxoisoindolin-2-yl)-4-carbamoylbutanoic acid.


2
Joseph Armstrong Martin, Keshab Sarma, David Bernard Smith, Mark Smith: Antiviral nucleoside derivatives. Roche Palo Alto, Brian L Buckwalter, January 25, 2005: US06846810 (86 worldwide citation)

The present invention relates to nucleoside derivatives for the treatment of Hepatitis C viral infections including compounds of formula I, pharmaceutical compositions comprising these compounds and methods for treatment or prophylaxis of Hepatitis C Virus mediated diseases employing said compounds ...


3

4
Byoung Kwon Chun, Jeremy Clark, Keshab Sarma, Peiyuan Wang: Antiviral nucleosides. Roche Palo Alto, Brian L Buckwalter, July 13, 2010: US07754699 (38 worldwide citation)

Compounds having the formula I wherein R1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, and processes for making the compounds of formula I


5
Joseph Armstrong Martin, Keshab Sarma, David Bernard Smith, Mark Smith: Anti-viral nucleosides. Roche Palo Alto, Brian L Buckwalter, May 27, 2008: US07378402 (24 worldwide citation)

4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (I:R1=R2=R3=R4=H) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for ...


6
Klaus Klumpp, Joseph Armstrong Martin, Christopher McGuigan, David Bernard Smith: Antiviral phosphoramidates. Roche Palo Alto, Brian L Buckwalter, October 27, 2009: US07608599 (20 worldwide citation)

The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediat ...


7
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Brian L Buckwalter, October 27, 2009: US07608601 (12 worldwide citation)

The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of ...


8
James Patrick Dunn, Steven Swallow, Zachary Kevin Sweeney: Non-nucleoside reverse transcriptase inhibitors. Roche Palo Alto, Brian L Buckwalter, April 24, 2007: US07208509 (12 worldwide citation)

This invention relates to novel heterocyclic compounds of formula I wherein R1—R4, X1 and X2 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, ...


9
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Brian L Buckwalter, December 6, 2011: US08071567 (12 worldwide citation)

The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.


10
Michelangelo Scalone, Helmut Stahr: Process for the preparation of a macrocycle. Roche Palo Alto, Brian L Buckwalter, January 31, 2012: US08106187 (12 worldwide citation)

The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein R1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.